SIX : NOVN.SW

Novartis AG

$126.9 CHF

-$0.76 (-0.6%)

Volume
1.86M
Average Volume
2.77M
Market Capitalization
$241.2B
P/E Ratio
23.55
Dividend Yield
2.92%
Price Target
Year High
$131.00
Year Low
$91.56
Day High
—
Day Low
—
Payout Ratio
$0.68
Current Ratio
$0.86
Company Overview

SIX

Vasant Narasimhan

Drug Manufacturers - General

Healthcare

NOVN.SW

75267

CH

CHF

https://www.novartis.com

41 61 324 1111

H5820Q150

N/A

Liquidity Metrics

1.18

0.86

0.67

0.24

0.68

Sales & Valuation

$57.13B

5.38

7.10

18.47

8.38

Profitability

$7.49

$14.65B

23.09%

28.09%

29.64%

10.34%

P/E Metrics

23.55

-5.24

-5.24

Analyst Price Target & Rating

Neutral

3/5

20 Analysts

%

Financial Health Scores

3.51

6/9

-$4.41B

$122.36B

$80.3B

$16.77B

Key Metrics (TTM)

No key metrics data available.

Company Executives
Name Title
Robert Kowalski Chief People & Organization Officer
Steffen Lang President of Operations
Vasant Narasimhan Chief Executive Officer
Evan Beckman Global Head of Translational Medicine at Novartis Institute for BioMedical Research
Karen L. Hale Chief Legal & Compliance Officer
Sloan Simpson Global Head of Investor Relations
Patrick Horber President of International
Paul Penepent Head of Group Financial Reporting and Accounting
Mukul Mehta Chief Financial Officer
Victor Bulto President of US
Poll Results

No votes yet today — be the first to share your view!

About Novartis AG (SIX:NOVN.SW) Stock

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acu ... te or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still’s disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Frequently Asked Questions

What is the current Novartis AG (NOVN.SW) stock price?

Novartis AG(SIX:NOVN.SW) stock price is $126.9 in the last trading session. During the trading session, NOVN.SW stock reached the peak price of $131 while $91.56 was the lowest point it dropped to. The percentage change in NOVN.SW stock occurred in the recent session was --0.6% while the dollar amount for the price change in NOVN.SW stock was -$0.76.

NOVN.SW's industry and sector of operation?

The SIX listed NOVN.SW is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.

Who are the executives of NOVN.SW?

Robert Kowalski | Chief People & Organization Officer
Steffen Lang | President of Operations
Vasant Narasimhan | Chief Executive Officer
Evan Beckman | Global Head of Translational Medicine at Novartis Institute for BioMedical Research
Karen L. Hale | Chief Legal & Compliance Officer

How many employees does NOVN.SW have?

Number of NOVN.SW employees currently stands at 75267. NOVN.SW operates from Lichtstrasse 35, Basel, BS 4056, CH.

Link for NOVN.SW official website?

Official Website of NOVN.SW is: https://www.novartis.com

How do I contact NOVN.SW?

NOVN.SW could be contacted at phone #41 61 324 1111 and can also be accessed through its website. NOVN.SW operates from Lichtstrasse 35, Basel, BS 4056, CH.

How many shares of NOVN.SW are traded daily?

The average number of NOVN.SW shares traded daily for last 3 months was 2.77M.

What is the market cap of NOVN.SW currently?

The market value of NOVN.SW currently stands at $241.2B with its latest stock price at $126.9